Pharvaris Presents Data at the 2024 Bradykinin Symposium Page 1

ZUG, Switzerland, Sept. 5, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced a summary of data presented at the ongoing 7th Bradykinin Symposium. Details of the presentations are outlined below:

Long-term safety and efficacy of oral deucrictibant for HAE prophylaxisa poster presentation by Marc A. Riedl, MD, MS In the current analysis of the ongoing open-label extension of the CHAPTER-1 Phase 2 trial, deucrictibant 40 mg/day was well tolerated, with no new safety signals observed. The results presented provide evidence for the long-term safety and efficacy of deucrictibant for the prevention of HAE attacks and support the further development of deucrictibant as a potential prophylactic therapy for HAE. Results from this analysis support that: